who reported non-CAR T and NK cells were predominantly CD7-, and restored lymphocytes to normal levels in approximately half of participants, in a 2-year follow-up of r/r T-ALL patients treated with donor-derived CD7 CAR T cells (30). This evidence concerns the gene CD7 and acute lymphoblastic leukemia.